交感性眼炎长期免疫调节与类固醇治疗的视力结局
该单中心回顾性比较临床研究纳入2005年3月至2022年10月治疗的交感性眼炎患者35例,随访1至17年,比较类固醇与免疫调节治疗的视力结局。结果显示免疫调节治疗在激素抵抗或复发性交感性眼炎中带来更优视力结局,而类固醇治疗可能对急性或难治性交感性葡萄膜炎有用但不足以长期控制炎症。
要点
- 更长的活动性葡萄膜炎和类固醇治疗时间与更高的视力丧失率相关
- 单独免疫调节治疗下更长的葡萄膜炎缓解期及无药缓解期与更低的视力丧失率相关
- 烷化剂或抗代谢药、生物反应调节剂与环孢素联合治疗更可能实现交感性眼炎缓解
核心结论
- 免疫调节治疗在激素抵抗或复发性交感性眼炎病例中带来更优的视力结局。
- 类固醇治疗可能对急性或难治性交感性葡萄膜炎有用,但不足以长期控制炎症。
研究设计与样本
- 单中心、回顾性、比较性临床研究。
- 纳入2005年3月至2022年10月治疗且随访至少1年的交感性眼炎患者35例,随访1至17年。
主要发现
- 更高的视力丧失率与更长的活动性葡萄膜炎和类固醇治疗时间相关。
- 更低的视力丧失率与单独免疫调节治疗下更长的葡萄膜炎缓解期及无药缓解期相关。
- 使用烷化剂或抗代谢药、生物反应调节剂与环孢素联合治疗更可能实现交感性眼炎缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare vision acuity outcomes of long-term steroid therapy compared with immunomodulatory therapy for treatment of sympathetic ophthalmia. DESIGN: Single-center, retrospective, comparative clinical study. METHODS: Patients with sympathetic ophthalmia treated from March 2005 to October 2022 with at least 1 year of follow-up were included. Visual acuity outcomes were compared by steroid and immunomodulatory treatment modality. RESULTS: Thirty-five patients with sympathetic ophthalmia were included in the study, with follow-up ranging from 1 to 17 years. Higher rates of vision loss correlated with longer periods of active uveitis and steroid treatment. Lower rates of vision loss correlated with longer periods of uveitis remission on immunomodulatory therapy alone and drug-free remission. Treatment with alkylating agents or combination therapy with an antimetabolite, a biologic-response modifier, and cyclosporine are more likely to result in sympathetic ophthalmia remission. CONCLUSION: Immunomodulatory therapy leads to superior vision outcomes in cases of steroid-resistant or recurrent sympathetic ophthalmia. Steroid therapy may be useful for acute or recalcitrant sympathetic uveitis but is insufficient for long-term inflammatory control. PRéCIS: This manuscript describes a retrospective analysis of vision outcomes in patients with sympathetic ophthalmia. Results indicate that long-term immunomodulatory therapy is associated with better vision outcomes than long-term steroid therapy for sympathetic ophthalmia treatment.
引用
- Zhou Y, Zhou A, Philip AM, et al. Vision Outcomes of Long-Term Immunomodulatory and Steroid Therapy in Sympathetic Ophthalmia. Am J Ophthalmol. 2023. PMID: 37150338. doi:10.1016/j.ajo.2023.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。